The Spot Sign for Predicting and Treating ICH Growth Study

NCT ID: NCT00810888

Last Updated: 2018-03-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-11-30
• Study Completion Date: 2016-04-30

Brief Summary

The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recombinant activated factor VII (rFVIIa) to placebo to determine the effect of rFVIIa on intracerebral hemorrhage growth.

Detailed Description

Intracerebral hemorrhage (ICH)-breakage of a blood vessel with bleeding in the brain-is a devastating form of stroke with a 40-50 percent fatality rate and no proven treatment. Because the majority of deaths from ICH occur within several days of the stroke, interventions for improving outcomes must occur early in the treatment course. Among the potentially modifiable determinants of ICH outcome, hematoma growth is a particularly attractive target for intervention and a major focus of this trial.

The purpose of this study is to determine if an imaging test called computed tomography angiography (CTA) can predict which individuals with ICH will experience significant growth in the size of the hemorrhage. Growth of the hemorrhage can cause additional injury and may worsen the outcome. For individuals who are at high risk for hemorrhage growth based on CTA results (i.e., a positive CTA "spot sign," evidence of contrast leakage within the hemorrhage), the study will compare the effects of a drug called recombinant activated factor VII (NovoSeven®) or rFVIIa with a placebo to determine which is better for reducing ICH growth.

The primary goals of this trial are (1) to determine the sensitivity and specificity of the CTA spot sign for predicting hematoma growth; (2) to determine the feasibility of using CTA to identify individuals with ICH who are at high risk of hematoma growth and to select study participants for randomization to treatment with rFVIIa or placebo; and (3) to determine the rate of hematoma growth among spot-positive individuals at 24 hours-comparing individuals treated with rFVIIa to those treated with placebo.

Approximately 184 persons with ICH will be enrolled in one of two study groups at 12 clinical sites across the United States and Canada. Participants with ICH who are determined by CTA to be at high risk for hemorrhage growth (CTA "spot sign" positive) will be randomized to receive either the active study medication, rFVIIa, at 80 mcg/kg, or to receive a placebo (an inactive substance). Participants with ICH who are determined by CTA not to be at high risk for hemorrhage growth (determined to be CTA "spot sign" negative) will be enrolled into a prospective observational group.

Duration of the study for participants is approximately 3 months.

Conditions

Intracerebral Hemorrhage

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Group 1-Recombinant activated factor VII

Participants with ICH determined by CTA to be high risk for hemorrhage growth ("spot sign" positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL).

Group Type: ACTIVE_COMPARATOR

recombinant activated factor VII

Intervention Type: DRUG

Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).

Group 2 - Placebo

Participants with ICH determined by CTA to be high risk for hemorrhage growth ("spot sign" positive for contrast leakage within the brain hematoma) will be randomized to receive placebo.

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)

Group 3 - Observation Only Arm

Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA "spot sign" negative) enrolled into a prospective observational group.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

recombinant activated factor VII

Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).

Intervention Type: DRUG

placebo

An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Acute, spontaneous ICH (including bleeding in cerebellum) diagnosed by non-enhanced CT scan within five hours of symptom onset. (Time of onset is defined as the last time the patient was witnessed to be at baseline (i.e., subjects who have stroke symptoms upon awakening will be considered to have their onset at beginning of sleep)
• Age >/= 18 years through 80 years (candidates must have had their 18th birthday, but not had their 81st birthday)
• For spot positive patients, dosing of study drug within 90 minutes of enrolling CT scan

Exclusion Criteria

• Time of symptom onset of ICH is unknown or more than five hours prior to baseline CT scan,
• ICH secondary to known or suspected trauma, aneurysm, vascular malformation, hemorrhagic conversion of ischemic stroke, venous sinus thrombosis, thrombolytic treatment of any condition (e.g., myocardial infarction, cerebral infarction, etc.), central nervous system (CNS) tumor or CNS infection
• Brainstem location of hemorrhage (patients with cerebellar hemorrhage may be enrolled)
• Serum creatinine > 1.4 mg/dl (123 μmol/L). Sites that currently perform CTA as standard of care for ICH will follow their standard procedures regarding renal insufficiency.
• Known allergy to iodinated contrast media
• Intravenous or intra-arterial administration of iodinated contrast media within the previous 24 hours of baseline CT scan
• Known hereditary (e.g., hemophilia) or acquired hemorrhagic diathesis, coagulation factor deficiency, or anticoagulant therapy with international normalized ration (INR) > 1.2
• Known or suspected thrombocytopenia (unless current platelet count documented above 50,000 / μl)
• Unfractionated heparin use with abnormal partial thromboplastin time (PTT)
• Low-molecular weight heparin use within the previous 24 hours
• GPIIb/IIIa antagonist use in the previous two weeks
• Direct thrombin inhibitor or factor Xa inhibitor within the previous 48 hours
• Glasgow Coma Scale score < 8 at time of proposed enrollment
• Pre-admission modified Rankin Scale score > 2
• Baseline ICH volume of < 0.5 cc (Hematoma volume will be estimated by local investigators from the baseline CT using the "ABC / 2 method".)
• Baseline ICH volume of > 90 cc
• Planned surgical evacuation of ICH within 24 hours of symptom onset (placement of intraventricular catheter is not a contraindication to study enrollment.)
• Evidence of acute or subacute ischemic stroke on baseline qualifying CT scan
• Clinical history of thromboembolism or ischemic vascular disease, including myocardial infarction, coronary artery bypass surgery, cardiac angina, transient ischemic attack, ischemic stroke, peripheral artery disease (vascular claudication), cerebral bypass surgery, carotid endarterectomy, deep venous thrombosis, pulmonary embolism, or coronary or cerebrovascular angioplasty or stenting. (Clinically silent evidence of old ischemia on EKG (Q waves) or CT scan (silent old infarct) will not be considered reasons for exclusion.)
• Baseline electrocardiogram shows evidence of acute cardiac ischemia (ST elevation in two contiguous leads, new left bundle branch block (LBBB), or ST depression)
• Clinical history suggestive of acute cardiac ischemia (e.g., chest pain)
• Abnormal baseline troponin
• Females of childbearing potential who are known to be pregnant and/or lactating or who have positive pregnancy tests on admission
• Advanced or terminal illness or any other condition the investigator feels would pose a significant hazard to the patient if rFVIIa were administered
• Recent (within 30 days) participation in any investigational drug or device trial or earlier participation in any investigational drug or device trial for which the duration of effect is expected to persist until the time of STOP-IT enrollment
• Planned withdrawal of care or comfort care measures
• Patient known or suspected of not being able to comply with trial protocol (e.g., due to alcoholism, drug dependency or psychological disorder)
• Informed consent cannot be obtained from the patient or legally authorized representative

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role: collaborator

University of Cincinnati

OTHER

Sponsor Role: lead

Responsible Party

Matthew Flaherty

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Matthew L. Flaherty, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

Edward C. Jauch, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Primary Emergency Medicine Investigator, Medical University of South Carolina

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

University of California, San Diego

San Diego, California, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Washington University

St Louis, Missouri, United States

University of Cincinnati-Clinical Coordinating Center

Cincinnati, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

University of Calgary

Calgary, Alberta, Canada

Sunnybrook Health Science Center

Toronto, Ontario, Canada

Countries

United States; Canada

References

Gladstone DJ, Aviv RI, Demchuk AM, Hill MD, Thorpe KE, Khoury JC, Sucharew HJ, Al-Ajlan F, Butcher K, Dowlatshahi D, Gubitz G, De Masi S, Hall J, Gregg D, Mamdani M, Shamy M, Swartz RH, Del Campo CM, Cucchiara B, Panagos P, Goldstein JN, Carrozzella J, Jauch EC, Broderick JP, Flaherty ML; SPOTLIGHT and STOP-IT Investigators and Coordinators. Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials. JAMA Neurol. 2019 Dec 1;76(12):1493-1501. doi: 10.1001/jamaneurol.2019.2636.

Reference Type: DERIVED

PMID: 31424491 (View on PubMed)

Related Links

http://www.STOPITSTUDY.org

trial website

Other Identifiers

2P50NS044283

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P50NS044283_STOP_IT

Identifier Type: -

Identifier Source: org_study_id